arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Fulgent Genetics, Inc.

FLGT Health Care Medical Specialities
$19.73
Today
as of Sep 4, 16:49 ET
Last 30 days +0.51% Jul 28 → Sep 04
$16.26 $17.32 $18.38 $19.44 $20.50 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$19.54
High
$19.86
Low
$19.38
Volume
$224,998
Avg Vol
$373,101
Mkt Cap
$513M
P/E (TTM)
—
Beta
—
52w High
$31.04
52w Low
$13.46
Div Yield
—
Shares Out
$28M

Recent Press Releases & News last 60 days · 8 items

Aug 8 · 02:14 Motley Fool
Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript
Aug 6 · 06:09 Simply Wall St.
Fulgent Genetics (FLGT) Stock Gets Fair Value Boost After Analysts Raised Targets
Jul 31 · 12:30 Moby
Fulgent Genetics, Inc. Q2 2026 Earnings Call Summary
▸ Show all 8 press releases & news Free account →

Overview

52-week range
$13
$31
36% of range
Avg surprise (last 2)
+47.7%
Avg reaction (last 1)
+19.1%
100% positive
Latest IV / EM
47%
EM ±7.3% · $20 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.56$-0.48$-0.41$-0.33$-0.25 Actual $-0.30Est $-0.50Actual $-0.25Est $-0.56 Mar/2025Jun/2025
Revenue vs Net Income Revenue Net income
$-30M$267,112$30M$60M$90M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Fri Aug 1, 2025Jun/2025 $-0.25 $-0.56 +55.4% — — earnings
Fri May 2, 2025Mar/2025 $-0.30 $-0.50 +40.0% — +19.1% earnings

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$85M$71M—$84M$82M$73M—$72M
Cost of revenue$60M$50M—$49M$47M$45M—$45M
Gross profit$26M$21M—$36M$34M$28M—$27M
Operating income$-36M$-35M—$-15M$-20M$-20M—$-17M
Net income$-30M$-25M—$-7M$-19M$-12M—$-15M
EPS (diluted)————————

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$26M$23M$50M$118M$88M$67M$55M$58M
Inventory$793,000$770,000——————
Total current assets$455M$479M$550M$507M$429M$417M$354M$327M
Total assets$1.09B$1.16B$1.21B$1.21B$1.20B$1.21B$1.22B$1.23B
Long-term debt————————
Total liabilities$93M$112M$107M$94M$88M$83M$91M$99M
Total equity$1.00B$1.04B$1.11B$1.13B$1.11B$1.12B$1.13B$1.13B

Implied volatility — last 90 days

24%98%171%244%317% Jun 07 — IV 77% · EM ±10.7%Jun 08 — IV 120% · EM ±15.8%Jun 09 — IV 70% · EM ±8.8%Jun 10 — IV 186% · EM ±21.9%Jun 11 — IV 128% · EM ±14.1%Jun 12 — IV 141% · EM ±14.5%Jun 15 — IV 218% · EM ±15.8%Jun 16 — IV 207% · EM ±12.2%Jun 17 — IV 318% · EM ±13.3%Jun 19 — IV 47% · EM ±10.4%Jun 22 — IV 48% · EM ±9.9%Jun 23 — IV 51% · EM ±10.5%Jun 24 — IV 61% · EM ±12.2%Jun 25 — IV 25% · EM ±4.9%Jun 26 — IV 50% · EM ±9.5%Jun 29 — IV 66% · EM ±11.7%Jun 30 — IV 61% · EM ±10.5%Jul 01 — IV 65% · EM ±10.8%Jul 02 — IV 59% · EM ±9.6%Jul 03 — IV 61% · EM ±9.6%Jul 06 — IV 125% · EM ±17.3%Jul 07 — IV 103% · EM ±13.6%Jul 08 — IV 77% · EM ±9.7%Jul 09 — IV 107% · EM ±12.7%Jul 10 — IV 70% · EM ±7.8%Jul 13 — IV 120% · EM ±10.0%Jul 14 — IV 84% · EM ±6.1%Jul 15 — IV 161% · EM ±9.5%Jul 16 — IV 239% · EM ±10.0%Jul 20 — IV 73% · EM ±17.3%Jul 21 — IV 65% · EM ±15.2%Jul 22 — IV 67% · EM ±15.2%Jul 23 — IV 78% · EM ±17.5%Jul 24 — IV 82% · EM ±18.0%Jul 27 — IV 81% · EM ±16.9%Jul 28 — IV 100% · EM ±20.4%Jul 29 — IV 84% · EM ±16.8%Jul 30 — IV 105% · EM ±20.5%Jul 31 — IV 73% · EM ±14.0%Aug 03 — IV 62% · EM ±10.9%Aug 04 — IV 54% · EM ±9.3%Aug 05 — IV 65% · EM ±10.8%Aug 06 — IV 64% · EM ±10.4%Aug 10 — IV 95% · EM ±13.1%Aug 11 — IV 139% · EM ±18.4%Aug 12 — IV 100% · EM ±12.6%Aug 13 — IV 84% · EM ±9.9%Aug 14 — IV 117% · EM ±12.9%Aug 17 — IV 99% · EM ±8.3%Aug 18 — IV 130% · EM ±9.4%Aug 19 — IV 269% · EM ±15.9%Aug 24 — IV 65% · EM ±13.6%Aug 25 — IV 61% · EM ±12.4%Aug 26 — IV 55% · EM ±11.0%Aug 27 — IV 42% · EM ±8.3%Aug 28 — IV 34% · EM ±6.5%Aug 31 — IV 58% · EM ±10.3%Sep 01 — IV 43% · EM ±7.4%Sep 02 — IV 46% · EM ±7.6%Sep 03 — IV 46% · EM ±7.4%Sep 04 — IV 47% · EM ±7.3%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in